Centre for Parasitology and Mycology, Instituto Adolfo Lutz, Av. Dr. Arnaldo, 351, São Paulo, SP, 01246-900, Brazil.
Mol Cell Biochem. 2014 Apr;389(1-2):293-300. doi: 10.1007/s11010-013-1954-6. Epub 2013 Dec 29.
Drug repositioning has been considered a promising approach to discover novel treatments against neglected diseases. Among the major protozoan diseases, leishmaniasis remains a public health threat with few therapeutic alternatives, affecting 12 million people in 98 countries. In this study, we report the in vitro antileishmanial activity of the imidazole drugs clotrimazole, and for the first time in literature, econazole and bifonazole and their potential action to affect the regulation of reactive oxygen species (ROS) of the parasites. The lethal action of the imidazoles was investigated using spectrofluorimetric techniques to detect ROS content, plasma membrane permeability, and mitochondrial membrane potential. The imidazoles showed activity against L. (L.) infantum chagasi promastigotes with IC50 values in a range of 2-8 μM; econazole was also effective against Leishmania intracellular amastigotes, with an IC50 value of 11 μM, a similar in vitro effectiveness to miltefosine. Leishmania promastigotes rapidly up-regulated the ROS release after incubation with the imidazoles, but econazole showed a marked increase in ROS content of approximately 1,900 % higher than untreated parasites. When using SYTOX(®) Green as a fluorescent probe, the imidazoles demonstrated considerable interference in plasma membrane permeability at the early time of incubation; econazole resulted in the higher influx of SYTOX(®) Green at 60 min. Despite cellular alterations, no depolarization could be observed to the mitochondrial membrane potential of Leishmania until 60 min. The lethal action of econazole involved strong permeabilization of plasma membrane of promastigotes, with an overloaded ROS content that contributed to the death of parasites. Affecting the ROS regulation of Leishmania via small molecules would be an interesting strategy for new drugs.
药物重定位被认为是发现针对被忽视疾病的新疗法的一种很有前途的方法。在主要的原生动物病中,利什曼病仍然是一个公共卫生威胁,几乎没有治疗选择,影响 98 个国家的 1200 万人。在这项研究中,我们报告了咪唑类药物克霉唑、酮康唑和联苯苄唑的体外抗利什曼原虫活性,这是文献中首次报道这些药物及其对调节寄生虫活性氧(ROS)的潜在作用。使用荧光光谱技术检测 ROS 含量、质膜通透性和线粒体膜电位来研究咪唑类药物的致死作用。咪唑类药物对 L.(L.)婴儿期前鞭毛体表现出活性,IC50 值在 2-8μM 范围内;酮康唑也对利什曼原虫内阿米巴原虫有效,IC50 值为 11μM,体外疗效与米替福新相似。利什曼原虫在与咪唑类药物孵育后迅速上调 ROS 的释放,但酮康唑使 ROS 含量增加了约 1900%,明显高于未处理的寄生虫。当使用 SYTOX(®)Green 作为荧光探针时,咪唑类药物在孵育的早期对质膜通透性有很大的干扰;酮康唑导致 SYTOX(®)Green 在 60 分钟时的内流增加。尽管细胞发生了改变,但直到 60 分钟,利什曼的线粒体膜电位才出现去极化。酮康唑的致死作用涉及到前鞭毛体质膜的强烈透化,ROS 含量过载,导致寄生虫死亡。通过小分子影响利什曼的 ROS 调节将是一种新药物的有趣策略。